{{medical}}
{{noteTA
|1=zh-hans:依达拉奉;
}}

{{Drugbox
 |IUPAC_name = 5-methyl-2-phenyl-4''H''-pyrazol-3-one
 | image=Edaravone Structural Formula V1.svg
 | image2=Edaravone ball-and-stick model.png
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 89-25-8
| ATC_prefix = none
| ATC_suffix = 
| PubChem = 4021
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3881
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = S798V6YJRP
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01552
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 31530
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 290916
| synonyms = MCI-186
| Drugs.com = 
 | legal_status = 
 | routes_of_administration=

<!--Chemical data-->
| C=10 | H=10 | N=2 | O=1
| molecular_weight = 174.20 g/mol
| smiles = O=C1N(/N=C(\C1)C)c2ccccc2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-6H,7H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = QELUYTUMUWHWMC-UHFFFAOYSA-N
}}

'''依达拉奉'''（英语：Edaravone，商品名：Radicut）是由日本[[田边三菱制药|田边三菱制药]]研发、生产和销售的一种抗氧化药物，用于清除自由基以治疗缺血性脑卒中等心脑血管疾病<ref name="pmid15049127">{{cite journal |vauthors=Watanabe T, Tanaka M, Watanabe K, Takamatsu Y, Tobe A | title = [Research and development of the free radical scavenger edaravone as a neuroprotectant] | language = ja | journal = Yakugaku Zasshi | volume = 124 | issue = 3 | pages = 99–111 |date=March 2004 | pmid = 15049127 | doi = 10.1248/yakushi.124.99| url = http://joi.jlc.jst.go.jp/JST.JSTAGE/yakushi/124.99?from=PubMed&lang=en}}</ref>。依达拉奉于2001年4月在日本上市,2015年依达拉奉的年销售额为1.69亿美元<ref>[http://www.evaluategroup.com/Universal/View.aspx?type=Entity&entityType=Product&lType=modData&id=50321&componentID=1002#&&_ViewArgs=%7b%22_EntityType%22%3a2%2c%22_Parameters%22%3a%7b%22_ContextData%22%3a%22%7b%5c%22componentID%5c%22%3a%5c%221003%5c%22%2c%5c%22itemID%5c%22%3a%5c%222367%5c%22%2c%5c%22lType%5c%22%3a%5c%22modData%5c%22%2c%5c%22pgaName%5c%22%3a%5c%22%5c%22%2c%5c%22reportingCurrency%5c%22%3a%5c%22%5c%22%2c%5c%22sceName%5c%22%3a%5c%22%5c%22%2c%5c%22tabId%5c%22%3a%5c%22%5c%22%2c%5c%22conceptTab%5c%22%3a%5c%22%5c%22%7d%22%7d%2c%22_Type%22%3a3%7d Evaluate Pharma]</ref>。

==研发历史==
早在1984年，具有酮-烯醇式同分异构体的酚类化合物的抗氧化活性就已经被自由基清除实验和脂过氧化物抑制等体外实验所证实。针对酮-烯醇式的化合物设计成为了依达拉奉的设计初衷<ref name="pmid18221078">{{cite journal |vauthors=Higashi Y, Jitsuiki D, Chayama K, Yoshizumi M | title = Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, for treatment of cardiovascular diseases | journal = Recent Patents on Cardiovascular Drug Discovery | volume = 1 | issue = 1 | pages = 85–93 |date=January 2006 | pmid = 18221078 | doi = 10.2174/157489006775244191| url = }}</ref>。动物模型和人体试验结果已经证实，依达拉奉可以有效防止缺血性脑卒中和再灌注损失后造成的脑水肿<ref name="pmid16834755">{{cite journal |vauthors=Yoshida H, Yanai H, Namiki Y, Fukatsu-Sasaki K, Furutani N, Tada N | title = Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury | journal = CNS Drug Reviews | volume = 12 | issue = 1 | pages = 9–20 | year = 2006 | pmid = 16834755 | doi = 10.1111/j.1527-3458.2006.00009.x }}</ref>。
==作用机理==

==适应症==

==不良反应==

==临床试验==


==参考文献==
{{Reflist}}

[[Category:抗氧化剂|Category:抗氧化剂]]